Lin Patrick 4

What Happened
Lin Patrick, Processa Pharmaceuticals' Chief Business & Strategy Officer, made an open-market purchase of 1,511 shares on 2026-04-30 at $2.69 per share, a total cost of roughly $4,065. This was a purchase (insider buying), which many investors watch as a potential positive signal, though the amount is small.

Key Details

• Transaction date: 2026-04-30 (reported on Form 4 filed 2026-05-01)
• Transaction type/code: Open-market purchase (P = Purchase)
• Price per share: $2.69; Shares acquired: 1,511; Total value: ~$4,065
• Shares owned after transaction: Not specified in the provided filing excerpt — see the Form 4 for total holdings.
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other footnotes were indicated in the provided excerpt.
• Timeliness: Filing date (2026-05-01) covers the 2026-04-30 transaction; no late-filing flag was indicated.

Context
This was a straightforward open-market purchase (no options exercised, no gifts or awards). The dollar amount is modest, so while insider purchases can be informative, this single small buy should be weighed with other insider activity and company fundamentals. For full ownership details and any notes, consult the complete Form 4 filing.